Brief: Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial
27/09/2021 14:33
Sept 27 (Reuters) - Hbm Holdings Ltd 2142.HK :
* HARBOUR BIOMED ANNOUNCES DOSING OF FIRST PATIENT OF
BATOCLIMAB
PHASE III TRIAL IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
Source text for Eikon: ID:nPnsLvFpa
Further company coverage: 2142.HK
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study